Patients with Friedreich’s ataxia may have more damage to brain cells than was previously thought. A study from University…
Maureen Newman
Maureen Newman is a researcher by trade, and brings her knowledge of the lab to BioNews Texas. Currently, she is serving as a PhD student at University of Rochester, and working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit’s laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment. She is a senior science and research columnist for BioNews Texas.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Maureen Newman
A research group in Germany at University of Regensburg that considers Friedreich’s ataxia “the most important recessive ataxia…
Inhibitors of 2-aminobenzamide histone deacetylase (HDAC) are a proposed new treatment for Friedreich’s ataxia. Applying HDAC inhibitors to neuronal…
The vast majority of patients with Friedreich’s ataxia develop symptoms in the first or second decade of life, enabling…
Although German physician Nikolaus Friedreich first recognized Friedreich’s ataxia in 1863, it was not until 1996 that two scientific…
At Baylor College of Medicine in Houston, Texas, researchers are developing a genetic toolkit to help study ataxia. Marife…
As the most prevalent form of ataxia, Friedreich’s ataxia represents a major focus for research in the field of understanding disease mechanisms.
Joining Friedreich’s Ataxia in the list of ataxias is spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease.
Earning the Pioneer SCA Translational Research Award from the National Ataxia Foundation, Thorsten Schmidt, PhD…
Reata Pharmaceuticals, Inc. has announced that it has enrolled the first patient in a new Friedreich’s Ataxia clinical trial in collaboration…